Intranasal Opioid Compositions

Abstract

The present invention relates to pharmaceutical compositions for intranasal administration to a mammal that contain an effective amount of an opioid, a liquid nasal carrier for the opioid, and optionally a sweetener, flavoring agent or masking agent. In some embodiments of the present invention, the pharmaceutical compositions have improved bioavailability. In other embodiments of the present invention, the opioid compositions improve patient compliance.

1 - 16 . (canceled)  
   
   
       17 . An intranasally deliverable pharmaceutical composition comprising: an effective amount of hydromorphone or a pharmaceutically acceptable salt thereof and a liquid nasal carrier substantially preservative-free wherein upon intranasal administration of the composition containing at least 2 mg of the hydromorphone or the salt thereof, the subject exhibits a C max  hydromorphone plasma concentration of at least about 3000 pg/mL.  
   
   
       18 . An intranasally deliverable pharmaceutical composition comprising an effective amount of hydromorphone or a pharmaceutically acceptable salt thereof, and a preservative-free liquid nasal carrier comprising sodium chloride, citric acid, and water.  
   
   
       19 - 23 . (canceled)  
   
   
       24 . A method of treating a mammal suffering from pain comprising intranasally administering to the mammal the composition of  claim 17  or  18 .  
   
   
       25 . (canceled)  
   
   
       26 . The pharmaceutical composition of  claim 17  or  18 , wherein the liquid nasal carrier comprises a buffering agent.  
   
   
       27 . The pharmaceutical composition of  claim 26 , wherein the buffering agent is selected from the group consisting of sodium citrate, sodium acetate, sodium phosphate, potassium phosphate and mixtures thereof.  
   
   
       28 . The pharmaceutical composition of  claim 27 , wherein the composition has a pH of about 3 to 7.  
   
   
       29 . The pharmaceutical composition of  claim 17  or  18 , wherein the buffering agent is present in the composition in a total amount of about 0.01% to 3% by weight.  
   
   
       30 . The pharmaceutical composition of  claim 17  or  18 , wherein the liquid nasal carrier comprises an aqueous diluent.  
   
   
       31 . The pharmaceutical composition of  claim 30 , wherein the aqueous diluent is selected from the group consisting of saline, water, dextrose or combinations thereof.